Citations Appearing in 2007

  1. Alexandre, J., E. Rey, V. Girre, S. Grabar, A. Tran, V. Montheil, F. Rabillon, V. Dieras, V. Jullien, P. Herait, G. Pons, J.M. Treluyer and F. Goldwasser. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Annals of Oncology 18(1):168-172, 2007.
  2. Ambrose, P.G., A. Forrest, W.A. Craig, C.M. Rubino, S.M. Bhavnani, G.L. Drusano,  and H.S. Heine. Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrobial Agents and Chemotherapy 51(10):4351-4355, 2007.
  3. Bakri, S.J., M.R. Snyder, J.M. Reid, J.S. Pulido and R.J. Singh. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 114(5):855-859, 2007.
  4. Bauer, R.J., S. Guzy and C. Ng. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. The AAPS Journal 9(1):E60-E83, 2007.
  5. Berg, S.L., C. Brueckner, J.G. Nuchtern, R. Dauser, L. McGuffey and S.M. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemotherapy and Pharmacology 59(6):743-747, 2007.
  6. Broniscer, A., J.C. Panetta, M. O’Shaughnessy, C. Fraga, F. Bai, M.J. Krasin, A. Gajjar and C.F. Stewart. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clinical Cancer Research 13(5):1511-1515, 2007.
  7. Chen, J., Q. Lu and J.P. Balthasar. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. Journal of Pharmacokinetics and Pharmacodynamics 34(6): 2007.
  8. Ferl, G.Z., X. Zhang, H. Wu and S. Huang . Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. Journal of Nuclear Medicine 48(12):2037-2045, 2007.
  9. Foster, D.R., K.M. Sowinski, H. Chow and B. Overholser. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions. Therapeutic Drug Monitoring 29(6):835-842, 2007.
  10. Garg, F. and J.P. Balthasar. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics 34(5): 2007.
  11. Gueorguieva, I., K. Ogungbenro, G. Graham, S. Glatt and L. Aarons. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Computer Methods and Programs in Biomedicine 86(1):51-61, 2007.
  12. Gumbo, T., A. Louie, W. Liu, P.G. Ambrose, S.M. Bhavnani, D. Brown, and G.L. Drusano. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of mycobacterium tuberculosis in the log phase of growth.The Journal of Infectious Diseases 195(2):194-201, 2007.
  13. Hazra, A., D.C. DuBois, R.R. Almon and W.J. Jusko. Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling. Journal of Pharmacokinetics and Pharmacodynamics 34(3):333-354, 2007.
  14. Hong, Y., D.E. Mager, R.A. Blum and W.J. Jusko. Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability. Pharmaceutical Research 24(6): 2007.
  15. Hope, W.W., G.L. Drusano, C.B. Moore, A. Sharp, A. Louie, T.J. Walsh, D.W. Denning, and P.A. Warn. The effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.Antimicrobial Agents and Chemotherapy 5(1):285-295, 2007.
  16. Hope, W.W., P.A. Warn, A. Sharp, P. Reed, B. Keevil, A. Louie, T.J. Walsh, D.W. Denning and G.L. Drusano. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrobial Agents and Chemotherapy 51(10):3760-3762, 2007.
  17. Hope, W.W., N.L. Seibel, C.L. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J.J. Keirns, D.N. Buell, T. Gumbo, G.L. Drusano and T.J. Walsh. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrobial Agents and Chemotherapy 51(10):3714-3719, 2007.
  18. Horton, T.M., D. Pati, S.E. Plon, P.A. Thompson, L.R. Bomgaars, P.C. Adamson, A.M. Ingle, J. Wright, A.H. Brockman, M. Paton and S.M. Blaney. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory Leukemia: a Children’s Oncology Group study. Clinical Cancer Research 13(5):1516-1522, 2007.
  19. Horton, T.M., P.A. Thompson, S.L. Berg, P.C. Adamson, A.M. Ingle, M. Eileen Dolan, S.M. Delaney, M. Hedge, H.L. Weiss, M. Wu and S.M. Blaney. Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children’s Oncology Group Study. Journal of Clinical Oncology 25(31):4922-4928, 2007.
  20. Javle, M.M., S. Cao, F.A. Durrani, L. Pendyala, D.D. Lawrence, P.F. Smith, P.J. Creaven, D.C. Noel, R.V. Iyer and Y.M. Rustum. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clinical Cancer Research 13(3):965-971, 2007.
  21. Laplanche R., G.M.L. Meno-Tetang and R. Kawai. Physiologically Based Pharmacokinetic (PBPK) Modeling of Everolimus (RAD001) in Rats Involving Non-Linear Tissue Uptake. Journal of Pharmacokinetics and Pharmacodynamics 34(3): 2007.
  22. Lim K., T. Lim and W. Wong. Pharmacokinetics Of Thiopental In Patients With Cardiovascular Disease.The Internet Journal of Anesthesiology 14(1): 2007.
  23. Lodise, T.P., B. Lomaestro and G.L. Drusano. Piperacillin-Tazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clinical Infectious Diseases 44(3):357-363, 2007.
  24. Lodise, T.P., R. Nau, M. Kinzig, G.L. Drusano, R.N. Jones and F. Sörgel. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. Journal of Antimicrobial Chemotherapy 60(5):1038-1044, 2007.
  25. Lodise, T.P., R. Pypstra, J.B. Kahn, B.P. Murthy, H.C. Kimko, K. Bush, G. Noel and G.L. Drusano. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents and Chemotherapy 5(1):Epub ahead of print, 2007.
  26. Madden, T., M. de Lima, N. Thapar, J. Nguyen, S. Roberson, D. Couriel, B. Pierre, E.J. Shpall, R.B. Jones, R.E. Champlin and B.S. Andersson. Pharmacokinetics of once-daily IV Busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biology of Blood and Marrow Transplantation 13(1):56-64, 2007.
  27. Metzger, M.L., C.F. Stewart, B.B. Freeman, III, C.A. Billups, F.A. Hoffer, J. Wu, M.J. Coppes, R. Grant, M. Chintagumpala, E.A. Mullen, C. Alvarado, N.C. Daw and J.S. Dome. Topotecan is active against Wilms’ tumor: results of a multi-institutional phase II study. Journal of Clinical Oncology 5(1):3130-3136, 2007.
  28. Meineke, I. and J. Brockmöller. Simulation of complex pharmacokinetic models in Microsoft EXCEL. Computer Methods and Programs in Biomedicine 88(3):239-245, 2007.
  29. Miller, A.A., D.J. Murry, K. Owzar, D.R. Hollis, L.D. Lewis, H.L. Kindler, J.L. Marshall, M.A. Villalona-Calero, M.J. Edelman, R.J. Hohl, S.M. Lichtman and M.J. Ratain. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Journal of Clinical Oncology 25(21):3055-3060, 2007.
  30. Mirochnick, M., J.H. Rodman, B.L. Robbins, A. Fridland, J. Gandía, J. Hitti, A. Bardeguez, M.H. Rathore, A. Gonzalez Garcia, M. Cababasay, P. Samson, L. Mofenson, Y. Bryson and A. Dorenbaum. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. HIV Medicine 8(7):451-456, 2007.
  31. Moreno, E.C., M.M. Sanjuan, V. Merino, A. Nacher, R.V. Martin Algarra and V.G. Casabo. Population modelling to describe pharmacokinetics of amiodarone in rats: Relevance of plasma protein and tissue depot binding. European Journal of Pharmaceutical Sciences 30(2):190-197, 2007.
  32. Okusanya, O., A. Forrest, R. Difrancesco, S. Bilic , S. Rosenkranz, M.F Para, E. Adams, K.E. Yarasheski, R.C. Reichman and G.D. Morse. Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrobial Agents and Chemotherapy 51(5):1822-1826, 2007.
  33. Quinn, D.I., J. Nemunaitis, J. Fuloria, C. D. Britten, N. Y. Gabrail, L. Yee, M. Acharya, K. C. Chan, P. Bishop, and A. P. Dudov. Open-label study to assess effect of omeprazole (O) on pharmacokinetics of bortezomib (B) in subjects with advanced solid tumors, NHL, or multiple myeloma. ASCO Meeting Abstracts 25:13000, 2007.
  34. Parker, R.S. Modeling for anti-cancer chemotherapy design. Journal of Process Control 17(7):576-582, 2007.
  35. Ramalingam, S.S., R.A. Parise, R.K. Ramananthan, T.F. Lagattuta, L.A. Musguire, R.G. Stoller, D.M. Potter, A.E. Argiris, J.A. Zwiebel, M.J. Egorin and C.P. Belani. Phase I and pharmacokinetic study of Vorinostat, a histone deacetylase inhibitor, in combination with Carboplatin and Paclitaxel for advanced solid malignancies.Clinical Cancer Research 13(12):3605-3610, 2007.
  36. Rubino, C.M., L. Ma, S.M. Bhavnani, J. Korth-Bradley, J. Speth, E. Ellis-Grosse, K.R. Rodvold, P.G. Ambrose and G.L. Drusano. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrobial Agents and Chemotherapy 51(11):4085-4089, 2007.
  37. Sakka, S.G., A.K. Glauner, J.B. Bulitta, M. Kinzig-Schippers, W. Pfister, G.L. Drusano and F. Sörgel. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy 51(9):3304-3310, 2007.
  38. Schaiquevich, P., J.C. Panetta, L.C. Iacono, B.B. Freeman, V.M. Santana, A. Gajjar and C.F. Stewart. Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients. Clinical Cancer Research 13:6703-6711, 2007.
  39. Schneider, B., A. Fukunaga, D. Murry, C. Yoder, K. Fife, A. Foster, L. Rosenberg, S. Kelich, L. Li and C. Sweeney. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-a2b in patients with solid tumors. Cancer Chemotherapy and Pharmacology 59(2):261-268, 2007.
  40. Seminari, E., A.D. Bona, G. Gentilini, L. Galli, G. Schira, N. Gianotti, C. Uberti-Foppa, A. Soldarini, F. Dorigatti, A. Lazzarin and A. Castagna. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. Journal of Antimicrobial Chemotherapy 60(4):831-836, 2007.
  41. Sermsappasuk, P., O. Abdelrahman and M. Weiss. Modeling cardiac uptake and negative inotropic response of verapamil in rat heart: effect of amiodarone.Pharmaceutical Research 24(1):48-57, 2007.
  42. Shibata, S., W. Chow, P. Frankel, A. Juhasz, L. Leong, D. Lim, K. Margolin, R. Morgan, E. Newman, G. Somlo, Y. Yen, T. Synold, D. Gandara, H. Lenz and J. Doroshow. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology 59(4):549-557, 2007.
  43. Smith, P.F., A. Ogundele, A. Forrest, J. Wilton, K. Salzwedel, J. Doto, G.P. Allaway and D.E. Martin. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 51(10):3574-3581, 2007.
  44. Spunt, S.L., B.B. Freeman, C.A. Billups, V. McPherson, R.B. Khan, C.B Pratt amd C.F. Stewart. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. Journal of Clinical Oncology 25(16):2274-2280, 2007.
  45. Stapleton, S.L., J.M. Reid, P.A. Thompson, M.M. Ames, R.M. McGovern, L. McGuffey, J. Nuchtern, R. Dauser and S.M. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemotherapy and Pharmacology 59(2):461-466, 2007.
  46. Stewart, C.F., J.C. Panetta, M.A. O’Shaughnessy, S.L. Throm, C.H. Fraga, T. Owens, T. Liu, C. Billups, C. Rodriguez-Galindo, A. Gajjar, W.L. Furman and L.M. McGregor. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. Journal of Clinical Oncology 25(18):2594-2600 2007.
  47. Tam, V.H., A Louie, M.R. Deziel, W. Liu, and G.L. Drusano. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrobial Agents and Chemotherapy 51(2):744-747, 2007.
  48. Tam, V.H., A Louie, T.R. Fritsche, M. Deziel, W. Liu, D.L. Brown, L. Deshpande, R. Leary, R.N. Jones and G.L. Drusano. Impact of drug-exposure intensity and duration of therapy on the emergence of staphylococcus aureus resistance to a quinolone antimicrobial. Journal of Infectious Diseases 195(12):1818-1827, 2007.
  49. Testart-Paillet, D., P. Girard, B. You, G. Freyer, C. Pobel and B. Tranchand. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Critical Reviews in Oncology/Hematology (B):1-11, 2007.
  50. Wang, Q. and M.E. Morris. Flavonoids modulate monocarboxylate transporter-1-mediated transport of {gamma}-hydroxybutyrate in vitro and in vivo. Drug Metabolism and Disposition 35(2):201-208, 2007.
  51. Weiss, M. Residence time dispersion as a general measure of drug distribution kinetics: estimation and physiological interpretation. Pharmaceutical Research 24(11):2025-2030, 2007.
  52. Weiss, M., T.C. Krejcie and M.J. Avram. A Minimal Physiological Model of Thiopental Distribution Kinetics Based on a Multiple Indicator Approach. Drug Metabolism and Disposition 35(9):1525-1532, 2007.
  53. Wetzler, M., J.C. Earp, .T.Brady, M.K. Keng and W.J. Jusko. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity—pharmacodynamicdrug-drug interaction modeling. Clinical Cancer Research 13(7):2261-2270, 2007.
  54. Woloszczuk-Gebicka, B., E. Wyska and T. Grabowski. Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis. Paediatric Anaesthesia 17(7):637-646, 2007.
  55. Woo, S., W. Krzyzanski and W.J. Jusko. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). Journal of Pharmacokinetics and Pharmacodynamics 34(6): 2007.
  56. Woo, S. and W.J. Jusko. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metabolism and Disposition 35(9):1672-1678, 2007.
  57. Xu, J., J. Winkler and H. Derendorf. A Pharmacokinetic/Pharmacodynamic Approach to Predict Total Prednisolone Concentrations in Human Plasma. Journal of Pharmacokinetics and Pharmacodynamics 34(3): 2007.
  58. Yua, Z., C. JIangb, Y. Guoa, Y. Hua and D. Chen. Pharmacokinetics of Flunixin Meglumine After Intravenous and Intramuscular Administration in Pigs. Agricultural Sciences in China 6(11):1396-1401,  2007.
  59. Yun, H., S. Bang, K. Lee, I. Baek, S. Lee, W. Kang and K. Kwon. Simultaneous analysis of naltrexone and its major metabolite, 6-?-naltrexol, in human plasma using liquid chromatography–tandem mass spectrometry: Application to a parent-metabolite kinetic model in humans. Talanta 71(4):1553-1559, 2007.